Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients.

IF 1.8 Q3 PHARMACOLOGY & PHARMACY
Eugene Chang, Aaron M Tejani
{"title":"Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients.","authors":"Eugene Chang, Aaron M Tejani","doi":"10.1093/ijpp/riaf077","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.</p><p><strong>Methods: </strong>A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.</p><p><strong>Key findings: </strong>Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.</p><p><strong>Conclusion: </strong>Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ijpp/riaf077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.

Methods: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.

Key findings: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.

Conclusion: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.

越大越好吗?香氛剂5与10mg治疗失眠症的疗效及安全性分析。
目的:评估使用leleborexant 10mg作为起始剂量或对5mg有部分反应的患者治疗失眠的合理性。方法:对MEDLINE、监管报告和加拿大药物和健康技术机构的数据进行回顾。主要发现:lelemborexant 10毫克作为初始剂量对睡眠指标的改善作用小于5毫克,但会增加嗜睡的风险。没有证据支持部分反应者增加剂量至5mg。结论:Lemborexant 10mg通常不建议作为初始剂量或升级剂量,因为较高的危害风险和不太可能的临床效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.90
自引率
5.60%
发文量
146
期刊介绍: The International Journal of Pharmacy Practice (IJPP) is a Medline-indexed, peer reviewed, international journal. It is one of the leading journals publishing health services research in the context of pharmacy, pharmaceutical care, medicines and medicines management. Regular sections in the journal include, editorials, literature reviews, original research, personal opinion and short communications. Topics covered include: medicines utilisation, medicine management, medicines distribution, supply and administration, pharmaceutical services, professional and patient/lay perspectives, public health (including, e.g. health promotion, needs assessment, health protection) evidence based practice, pharmacy education. Methods include both evaluative and exploratory work including, randomised controlled trials, surveys, epidemiological approaches, case studies, observational studies, and qualitative methods such as interviews and focus groups. Application of methods drawn from other disciplines e.g. psychology, health economics, morbidity are especially welcome as are developments of new methodologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信